Agios Pharmaceuticals (AGIO) Retained Earnings (2012 - 2026)

Agios Pharmaceuticals has reported Retained Earnings for 15 years, with the latest figure at -$660.8 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 177.41% year-over-year to -$660.8 million; the trailing twelve-month figure through Mar 2026 stood at -$660.8 million (down 177.41% YoY), and the FY2025 full-year result was -$561.7 million, down 277.18% from the prior year.
• Retained Earnings for Q1 2026 stood at -$660.8 million, down from -$561.7 million in the prior quarter.
• The five-year high for Retained Earnings was -$52.4 million in Q3 2024, with the low at -$1.0 billion in Q2 2024.
• Historically, Retained Earnings has averaged -$520.2 million across 5 years, with a median of -$507.1 million in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 1181.15% — and 2024, when it soared 92.79%.
• Agios Pharmaceuticals' Retained Earnings stood at -$470.6 million in 2022, then tumbled by 74.82% to -$822.6 million in 2023, then jumped by 81.9% to -$148.9 million in 2024, then slumped by 277.18% to -$561.7 million in 2025, then dropped by 17.64% to -$660.8 million in 2026.
• The last three Retained Earnings figures came in at -$660.8 million (Q1 2026), -$561.7 million (Q4 2025), and -$453.7 million (Q3 2025), per Business Quant data.